Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV-Reference-Cited by-同舟云学术

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Published:2015-02-13 Issue:5 Volume:29 Page:1123-1132
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kalmanti L, ,Saussele S,Lauseker M,Müller M C,Dietz C T,Heinrich L,Hanfstein B,Proetel U,Fabarius A,Krause S W,Rinaldetti S,Dengler J,Falge C,Oppliger-Leibundgut E,Burchert A,Neubauer A,Kanz L,Stegelmann F,Pfreundschuh M,Spiekermann K,Scheid C,Pfirrmann M,Hochhaus A,Hasford J,Hehlmann R

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201536.pdf

Reference47 articles.

1. O'Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.

3. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054–1061.

4. Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 2013; 121: 3818–3824.

5. Falchi L, Kantarjian HM, Wang X, Verma D, Quintas-Cardama A, O'Brien S et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 2013; 88: 1024–1029.

Cited by 232 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events;Molecular Metabolism;2024-10

2. Analysis of the pharmacoeconomic effectiveness of the tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia in a Single Hematology Center in Plovdiv, Bulgaria;Pharmacia;2024-06-26

3. Computational modeling reveals key factors driving treatment-free remission in chronic myeloid leukemia patients;npj Systems Biology and Applications;2024-04-27

4. A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia;Expert Opinion on Drug Safety;2024-04

5. Recent Trends in Nanomaterial Based Electrochemical Sensors for Drug Detection: Considering Green Assessment;Current Topics in Medicinal Chemistry;2024-04